ReviewNature reviews. Drug discovery2015
A decade of innovation in pharmaceutical R&D: the Chorus model.
Review in Nature reviews. Drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.Clinical and translational science · 2023Pooled it
- De-risking vaccine development: lessons, challenges, and prospects.NPJ vaccines · 2025Review
- Brain functional connectivity correlates of autism diagnosis and familial liability in 24-month-olds.Journal of neurodevelopmental disorders · 2025Article
- The Role of Cross-Institutional and Interdisciplinary Collaboration in Defining and Executing a Quantitative Systems Pharmacology Strategy.Handbook of experimental pharmacology · 2025Review
- Technology Readiness Level Roadmap for Developing Innovative Herbal Medicinal Products.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Achieving end-to-end success in the clinic: Pfizer's learnings on R&D productivity.Drug discovery today · 2022Article
- Review
- Phase 0/microdosing approaches: time for mainstream application in drug development?Nature reviews. Drug discovery · 2020Review
- Expedited Safety Reporting to Sponsors Through the Implementation of an Alert System for Clinical Trial Management at an Academic Medical Center: Retrospective Design Study.JMIR medical informatics · 2020Article
- Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work.European journal of medicinal chemistry · 2019Review
- Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.Pharmaceutical medicine · 2019Review
- Drugs' development in acute heart failure: what went wrong?Heart failure reviews · 2018Review
- Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?Journal of translational medicine · 2018Review
- Impact of a five-dimensional framework on R&D productivity at AstraZeneca.Nature reviews. Drug discovery · 2018Article
- Has molecular imaging delivered to drug development?Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2017Review
- The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures.Clinical and translational science · 2017Article
- Drug discovery and development: Role of basic biological research.Alzheimer's & dementia (New York, N. Y.) · 2017Review
- An iterative compound screening contest method for identifying target protein inhibitors using the tyrosine-protein kinase Yes.Scientific reports · 2017Article
- Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets.Biomedicines · 2016Review
- Changing R&D models in research-based pharmaceutical companies.Journal of translational medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chorus is a small, operationally independent clinical development organization within Eli Lilly and Company that specializes in drug development from candidate selection to clinical proof of concept. The mission of Chorus is to achieve proof of concept rapidly and at a low cost while positioning successful projects for 'pharma-quality' late-stage development. Chorus uses a small internal staff of experienced drug developers and a network of external vendors to design and implement chemistry, manufacturing and control processes, preclinical toxicology and biology, and Phase I/II clinical trials. In the decade since it was established, Chorus has demonstrated substantial productivity improvements in both time and cost compared to traditional pharmaceutical research and development. Here, we describe its development philosophy, organizational structure, operational model and results to date.
Indexed as
Identifiers
25503514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.